John Murphy, CEO, COVID-19 Long-Haul Foundation

Abstract

Importance

More than six years after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), post-acute sequelae of COVID-19 (PASC), commonly known as Long COVID, remains a major public health challenge. Although numerous mechanisms have been proposed to explain persistent symptoms, accumulating evidence suggests that viral persistence or persistence of viral material may represent a central pathophysiologic driver in at least a subset of affected individuals. Detection of viral RNA, spike protein, nucleocapsid protein, and replication-competent virus months to years after acute infection has fundamentally altered understanding of the disease.

Objective

To review current evidence supporting persistent viral material in Long COVID, examine mechanisms responsible for viral persistence, evaluate clinical significance, and discuss emerging therapeutic strategies.

Evidence Review

A comprehensive review of experimental, translational, and clinical studies investigating SARS-CoV-2 persistence was performed. Data from autopsy investigations, tissue biopsy studies, blood biomarker analyses, immunologic investigations, imaging studies, and therapeutic trials were integrated into a unified pathophysiologic framework.

Findings

Persistent SARS-CoV-2 RNA, proteins, and viral remnants have been identified in gastrointestinal tissue, lymphoid tissue, nervous system structures, vascular endothelium, bone marrow, reproductive organs, and circulating monocytes months after acute infection. Several studies have demonstrated persistence extending beyond two years. Viral persistence appears capable of inducing chronic immune activation, endothelial dysfunction, microvascular injury, mitochondrial impairment, neuroinflammation, autonomic dysfunction, and aberrant coagulation. Clinical manifestations associated with persistence include fatigue, post-exertional symptom exacerbation, dysautonomia, cognitive dysfunction, neuropathy, gastrointestinal abnormalities, and multisystem inflammatory syndromes.

Conclusions and Relevance

The growing body of evidence supporting persistent viral material has transformed understanding of Long COVID. Viral persistence represents one of the strongest biologically plausible mechanisms linking acute SARS-CoV-2 infection with chronic multisystem disease. Future therapeutic approaches may require combinations of antiviral, immunomodulatory, endothelial-protective, and metabolic therapies tailored to distinct biological phenotypes.

Introduction

The emergence of Long COVID represents one of the most significant medical developments of the twenty-first century. Although millions recover completely from acute SARS-CoV-2 infection, a substantial proportion experience prolonged symptoms extending months or years beyond the initial illness. These manifestations encompass nearly every organ system and often result in profound disability.

Early in the pandemic, prevailing assumptions held that SARS-CoV-2 behaved similarly to many respiratory viruses, producing acute illness followed by complete viral clearance. Persistent symptoms were therefore attributed primarily to post-infectious immune dysfunction, psychological factors, deconditioning, or irreversible tissue damage sustained during acute infection.

Over time, however, these assumptions became increasingly difficult to reconcile with emerging observations. Investigators repeatedly identified viral proteins, viral RNA, and viral antigens in tissues long after apparent recovery. Independent laboratories across multiple continents reported remarkably similar findings, suggesting that persistence of viral material may be neither rare nor incidental.

The concept of viral persistence is not unprecedented. Numerous pathogens establish chronic reservoirs despite apparent clinical recovery. Examples include human immunodeficiency virus, Epstein-Barr virus, varicella-zoster virus, hepatitis B virus, hepatitis C virus, Ebola virus, and measles virus. Persistent viral antigens have long been recognized as drivers of chronic inflammation and immune dysregulation.

The possibility that SARS-CoV-2 may establish prolonged tissue reservoirs has therefore become one of the most intensely investigated areas of Long COVID research.

This review examines the biological basis for viral persistence, evaluates evidence supporting persistent viral material, and explores implications for diagnosis and treatment.

Historical Development of the Viral Persistence Hypothesis

During the first months of the pandemic, SARS-CoV-2 was largely viewed as a transient respiratory infection. This assumption stemmed from prior experiences with endemic coronaviruses, which typically produce short-lived illnesses.

Several observations soon challenged this perspective.

Patients recovering from mild infections reported fatigue, cognitive impairment, dysautonomia, exercise intolerance, anosmia, neuropathy, and cardiopulmonary symptoms persisting for months. These complaints frequently occurred despite normal imaging studies and standard laboratory tests.

Investigators initially proposed:

Autoimmunity
Persistent inflammation
Endothelial injury
Microvascular dysfunction
Autonomic dysregulation
Mitochondrial dysfunction

While these mechanisms undoubtedly contribute, none adequately explained all clinical observations.

The first major clue emerged from gastrointestinal investigations. Researchers discovered SARS-CoV-2 RNA and proteins in intestinal tissue months after respiratory clearance. These findings suggested that the virus could establish reservoirs outside the respiratory tract.

Subsequent studies expanded the list of affected tissues dramatically.

Evidence accumulated for persistence in:

Intestinal mucosa
Lymph nodes
Bone marrow
Nervous system tissues
Reproductive organs
Cardiovascular tissues
Adipose tissue
Liver
Spleen

By 2024 and 2025, viral persistence had evolved from a controversial hypothesis into a major area of biomedical investigation.

Virologic Basis for Persistence

Unique Properties of SARS-CoV-2

Several characteristics make SARS-CoV-2 particularly capable of establishing tissue reservoirs.

Broad Tissue Tropism

The ACE2 receptor is widely distributed throughout the body.

Expression occurs in:

Lung
Intestine
Heart
Kidney
Endothelium
Brain
Testis
Pancreas
Adrenal tissue

Consequently, SARS-CoV-2 possesses an extraordinary capacity to infect multiple organ systems.

Immune Evasion

SARS-CoV-2 employs numerous strategies that blunt innate immune responses.

Mechanisms include:

Suppression of interferon signaling
Altered antigen presentation
Disruption of dendritic cell function
T-cell exhaustion
Monocyte reprogramming

These adaptations may facilitate incomplete viral clearance.

Reservoir Formation

Following acute infection, residual infected cells may persist within immunologically protected niches.

Potential reservoirs include:

Gut-associated lymphoid tissue
Central nervous system
Bone marrow
Lymphatic tissue
Reproductive organs

Such environments may permit persistence despite circulating antibodies.

Tissue Reservoirs and Viral Persistence

Gastrointestinal Reservoirs

The gastrointestinal tract currently represents the strongest candidate for long-term SARS-CoV-2 persistence.

The intestine contains:

Extensive ACE2 expression
Massive immune cell populations
Large mucosal surface area

Biopsy studies have repeatedly identified:

Viral RNA
Spike protein
Nucleocapsid protein

Months after acute infection.

Persistence within intestinal tissue may have profound systemic consequences because the gut serves as the largest immune organ in the body.

Chronic antigen exposure may continuously stimulate immune responses, sustaining inflammation throughout the organism.

Lymphoid Tissue Reservoirs

Lymphoid structures are uniquely suited for prolonged antigen retention.

Investigators have reported viral components within:

Lymph nodes
Tonsils
Peyer’s patches
Spleen

Persistence within these tissues may drive chronic immune activation and abnormal cytokine production.

Monocyte Reservoirs

One of the most intriguing discoveries involves persistence within circulating monocytes.

Monocytes function as mobile immune cells that patrol the body.

Several studies have demonstrated:

Spike protein persistence
Altered inflammatory profiles
Enhanced cytokine production

Months following infection.

These cells may act as vehicles distributing viral antigens throughout multiple organs.

Nervous System Reservoirs

Neurologic manifestations are among the most disabling features of Long COVID.

Investigators have detected viral material in:

Olfactory tissues
Brainstem structures
Cranial nerves
Meningeal tissues

Potential consequences include:

Neuroinflammation
Microglial activation
Synaptic dysfunction
Neurotransmitter abnormalities

Such findings may help explain cognitive dysfunction, memory impairment, autonomic instability, and sensory disturbances.

Evidence From Autopsy Studies

Autopsy investigations have provided some of the strongest evidence supporting persistence.

Comprehensive tissue analyses have demonstrated viral RNA in multiple organs months following acute infection.

Affected tissues include:

Heart
Brain
Intestine
Adrenal gland
Lymphoid tissues
Skeletal muscle

Importantly, several studies identified viral material in patients who died long after initial infection.

These findings suggest that viral remnants may remain distributed throughout the body for prolonged periods.

The breadth of tissue involvement indicates that Long COVID should be viewed as a systemic disease rather than a localized respiratory disorder.

Evidence From Gastrointestinal Biopsy Studies

Among living patients, gastrointestinal biopsy investigations have generated particularly compelling evidence.

Researchers performing endoscopy frequently identified:

Viral RNA
Spike protein
Nucleocapsid protein

Months after acute infection.

In some cases, persistent viral material was associated with:

Altered microbiome composition
Increased intestinal permeability
Local inflammatory infiltrates

The gastrointestinal tract therefore may function as a chronic antigen reservoir capable of sustaining systemic immune activation.

Evidence From Blood Biomarker Studies

A growing number of studies have reported detectable viral proteins in blood samples from Long COVID patients.

Detected biomarkers include:

Spike protein
S1 subunit
Nucleocapsid fragments

Persistence of circulating antigens has been associated with:

Fatigue
Cognitive dysfunction
Dysautonomia
Exercise intolerance

The presence of viral proteins in peripheral blood provides a plausible mechanistic link between tissue reservoirs and systemic symptoms.

Mechanisms Through Which Persistent Viral Material Produces Disease

Persistent viral material need not represent active infection to cause pathology.

Even nonreplicating viral proteins can exert potent biological effects.

Major mechanisms include:

Chronic immune stimulation
Endothelial activation
Microvascular injury
Coagulation abnormalities
Autoimmune activation
Mitochondrial dysfunction
Neuroinflammation
Dysautonomia

These processes interact to produce the complex clinical phenotype recognized as Long COVID.

Chronic Immune Activation

The immune system evolved to eliminate pathogens.

When viral antigens remain present indefinitely, immune activation may become chronic.

Consequences include:

Elevated cytokines
Persistent inflammation
T-cell exhaustion
B-cell dysregulation
Reduced immune resilience

This chronic activation resembles mechanisms observed in HIV, hepatitis C, and other persistent infections.

Endothelial Dysfunction

The vascular endothelium regulates blood flow, coagulation, and inflammatory signaling.

Spike protein has demonstrated direct effects on endothelial cells.

Persistent antigen exposure may induce:

Endothelial activation
Vasoconstriction
Increased permeability
Prothrombotic states

These abnormalities appear central to Long COVID pathophysiology.

Part II: Pathology, Physiology, Immune Dysregulation, and Organ-System Consequences

Pathology of Persistent Viral Material

A central question in Long COVID research concerns the distinction between persistent viral material and persistent productive infection. Although the terms are often used interchangeably in public discussion, they represent biologically distinct phenomena.

Persistent productive infection implies ongoing viral replication capable of generating infectious virions. Persistent viral material, by contrast, encompasses a spectrum of findings including residual genomic RNA, subgenomic RNA, spike protein, nucleocapsid protein, fragmented viral particles, defective viral genomes, and infected cells harboring viral components.

Importantly, even in the absence of active viral replication, persistent viral antigens may remain biologically active.

The pathology observed in Long COVID appears less consistent with overwhelming viral cytotoxicity than with chronic antigen-driven tissue injury. Persistent viral proteins may continuously stimulate innate and adaptive immune responses, producing a self-sustaining inflammatory state characterized by endothelial activation, aberrant coagulation, mitochondrial dysfunction, and neuroimmune signaling abnormalities.

This distinction is clinically significant because it suggests that therapies directed solely toward suppressing inflammation may fail if antigenic drivers remain present.

Histopathologic Findings

Histopathologic studies have demonstrated several recurring abnormalities among Long COVID patients.

Common findings include:

Chronic Lymphocytic Infiltration

Affected tissues frequently demonstrate infiltration by:

CD4+ T lymphocytes
CD8+ T lymphocytes
Activated macrophages
Plasma cells

These infiltrates are generally less intense than those observed during acute infection but persist far longer.

Microvascular Abnormalities

Small-vessel pathology frequently includes:

Endothelial swelling
Capillary rarefaction
Perivascular inflammation
Microthrombi
Fibrin deposition

These abnormalities may contribute to impaired oxygen delivery despite normal macroscopic circulation.

Persistent Macrophage Activation

Macrophages containing viral proteins have been observed in multiple tissues.

These cells may serve as long-term antigen reservoirs capable of sustaining inflammatory cytokine production.

Fibrotic Remodeling

Some tissues exhibit:

Collagen deposition
Extracellular matrix remodeling
Microfibrosis

Fibrotic changes may contribute to irreversible organ dysfunction in a subset of patients.

Cellular Physiology of Viral Persistence

At the cellular level, persistent viral material appears capable of disrupting multiple regulatory systems simultaneously.

The result is not a single disease process but rather a complex network of interacting physiologic disturbances.

Major affected systems include:

Innate immunity
Adaptive immunity
Mitochondrial metabolism
Endothelial signaling
Autonomic regulation
Neuroimmune communication

Each contributes to symptom generation.

Innate Immune Dysregulation

The innate immune system serves as the body’s first line of defense against infection.

Persistent viral proteins may chronically activate:

Toll-like receptors
NOD-like receptors
Inflammasomes
Interferon pathways

This activation produces sustained secretion of inflammatory mediators including:

Interleukin-1β
Interleukin-6
Tumor necrosis factor-alpha
Interferon-gamma

Although often subtle, chronic elevations may have profound physiologic consequences.

Patients frequently report symptoms resembling persistent influenza despite absence of active infection.

These symptoms include:

Malaise
Fatigue
Myalgias
Cognitive slowing
Sleep disturbances

Such manifestations may reflect chronic innate immune activation.

T-Cell Dysfunction and Exhaustion

One of the most reproducible immunologic findings in Long COVID involves abnormalities of T-cell function.

Persistent antigen exposure may drive T-cell exhaustion, a phenomenon previously described in HIV, hepatitis B, hepatitis C, and chronic viral infections.

Characteristics include:

Reduced proliferative capacity
Impaired cytokine production
Altered cytotoxic function
Expression of exhaustion markers

Exhausted T cells become progressively less effective at eliminating infected cells.

The resulting cycle may permit continued antigen persistence while simultaneously impairing immune surveillance.

Clinically, T-cell exhaustion may contribute to:

Fatigue
Recurrent infections
Delayed recovery
Reduced exercise tolerance

B-Cell Dysregulation

B-cell abnormalities have emerged as another major feature of Long COVID.

Persistent antigen exposure may result in:

Expansion of activated B-cell populations
Altered antibody production
Autoantibody generation
Loss of immune tolerance

Several studies have identified autoantibodies directed against:

Adrenergic receptors
Muscarinic receptors
Endothelial structures
Nuclear antigens
Phospholipid-associated proteins

Such autoantibodies may contribute to autonomic dysfunction and vascular abnormalities.

Monocyte and Macrophage Reservoirs

Monocytes and macrophages occupy a central position in contemporary models of Long COVID.

These cells possess several characteristics that make them ideal reservoirs:

Long lifespan
Broad tissue distribution
Capacity to migrate between organs
Resistance to immune elimination

Persistent spike protein has been identified within nonclassical monocytes months after acute infection.

These cells demonstrate:

Increased inflammatory activity
Enhanced cytokine production
Abnormal endothelial interactions

As mobile reservoirs, they may disseminate inflammatory signals throughout the body.

Mitochondrial Dysfunction

Mitochondria generate the majority of cellular energy through oxidative phosphorylation.

A growing body of evidence suggests persistent viral material may interfere with mitochondrial function through multiple mechanisms.

Potential effects include:

Reduced ATP production
Increased oxidative stress
Impaired fatty acid oxidation
Altered calcium regulation
Abnormal metabolic signaling

The consequences are particularly significant in tissues with high energy requirements.

Examples include:

Skeletal muscle
Brain
Heart
Peripheral nerves

Mitochondrial dysfunction may therefore explain several hallmark Long COVID symptoms:

Fatigue
Exercise intolerance
Post-exertional symptom exacerbation
Muscle weakness
Cognitive dysfunction

Oxidative Stress

Persistent immune activation generates reactive oxygen species.

When antioxidant defenses become overwhelmed, oxidative stress develops.

Consequences include:

DNA damage
Protein misfolding
Lipid peroxidation
Mitochondrial injury
Cellular senescence

Oxidative stress amplifies inflammation, creating a vicious cycle.

This self-reinforcing process may contribute to prolonged disease duration.

Endothelial Dysfunction

The vascular endothelium is increasingly recognized as a principal target of persistent viral material.

Endothelial cells regulate:

Blood flow
Coagulation
Vascular tone
Inflammatory signaling

Persistent spike protein exposure may induce:

Endothelial activation
Increased permeability
Vasoconstriction
Procoagulant signaling

These abnormalities can impair microcirculatory function despite normal large-vessel blood flow.

Microvascular Disease

Microvascular injury represents one of the most compelling explanations for the multisystem nature of Long COVID.

Every organ depends upon intact microcirculation.

Consequently, widespread capillary dysfunction can affect:

Brain
Heart
Muscle
Kidney
Peripheral nerves
Skin

Observed abnormalities include:

Microthrombi
Capillary obstruction
Reduced tissue perfusion
Endothelial inflammation

Even modest reductions in oxygen delivery may produce significant symptoms.

Fibrin Amyloid Microclots

Among the most debated findings in Long COVID research is the identification of abnormal fibrin amyloid microclots.

These structures exhibit:

Resistance to fibrinolysis
Entrapment of inflammatory molecules
Altered rheologic properties

Theoretical consequences include:

Reduced capillary flow
Tissue hypoxia
Impaired nutrient delivery
Exercise intolerance

Although the precise clinical significance remains under investigation, the concept has generated substantial research interest.

Neuroinflammation

Neurologic symptoms rank among the most disabling manifestations of Long COVID.

Persistent viral material may contribute through several mechanisms.

Direct Antigen Persistence

Viral proteins have been identified within:

Olfactory tissues
Cranial nerves
Brain-associated immune cells

Microglial Activation

Microglia serve as the resident immune cells of the central nervous system.

Persistent antigen exposure may induce chronic activation.

Activated microglia release:

Cytokines
Reactive oxygen species
Excitatory neurotransmitters

Excessive activation may impair neuronal function.

Blood-Brain Barrier Dysfunction

Inflammation may increase permeability of the blood-brain barrier.

Consequences include:

Entry of inflammatory mediators
Immune-cell trafficking
Neurovascular injury

These mechanisms likely contribute to cognitive dysfunction.

Cognitive Dysfunction (“Brain Fog”)

Brain fog remains among the most common Long COVID complaints.

Patients frequently describe:

Reduced concentration
Memory impairment
Word-finding difficulty
Executive dysfunction
Slowed information processing

The syndrome likely reflects convergence of multiple mechanisms:

Neuroinflammation
Microvascular dysfunction
Mitochondrial impairment
Autonomic instability

No single mechanism fully explains observed symptoms.

Dysautonomia

Autonomic dysfunction affects a substantial proportion of Long COVID patients.

Common manifestations include:

Orthostatic intolerance
Tachycardia
Temperature dysregulation
Gastrointestinal dysmotility
Exercise intolerance

Persistent viral material may contribute through:

Autoimmune mechanisms
Neural inflammation
Brainstem dysfunction
Vascular abnormalities

These pathways are not mutually exclusive.

Peripheral Neuropathy

Numerous patients develop sensory and motor abnormalities.

Symptoms include:

Numbness
Burning pain
Tingling
Weakness
Balance disturbances

Potential mechanisms include:

Small-fiber neuropathy
Microvascular ischemia
Immune-mediated injury
Persistent inflammatory signaling

The clinical phenotype often resembles other chronic neuroimmune disorders.

Cardiovascular Consequences

Persistent viral material may affect cardiovascular physiology through:

Endothelial injury
Autonomic dysfunction
Microvascular disease
Chronic inflammation

Potential outcomes include:

Reduced exercise capacity
Chest discomfort
Palpitations
Postural tachycardia
Exertional dyspnea

Notably, many affected individuals demonstrate normal conventional cardiac testing despite significant symptoms.

Renal Implications

Kidneys possess abundant ACE2 expression and are highly vulnerable to microvascular injury.

Potential consequences include:

Reduced glomerular filtration
Tubular dysfunction
Endothelial injury
Progressive chronic kidney disease

Persistent inflammatory signaling may accelerate renal decline in susceptible individuals.

A Unified Physiologic Model

Current evidence supports a multifactorial model.

Persistent viral material may initiate:

Chronic antigen exposure
Innate immune activation
Adaptive immune dysregulation
Endothelial dysfunction
Microvascular injury
Mitochondrial impairment
Neuroinflammation
Autonomic instability

These processes interact continuously.

The resulting network produces the heterogeneous clinical manifestations observed in Long COVID.

Part III: Clinical Significance, Diagnostic Approaches, Therapeutic Strategies, Future Directions, Conclusions, and References

Clinical Significance of Persistent Viral Material

The discovery of persistent SARS-CoV-2 material has profound implications for understanding Long COVID. The importance of these findings extends beyond mechanistic curiosity. If persistent viral antigens contribute directly to disease pathogenesis, they represent potentially modifiable therapeutic targets.

Historically, post-viral syndromes were often conceptualized as consequences of tissue damage incurred during acute infection. Under this model, chronic symptoms reflected residual injury rather than ongoing biologic processes. Persistent viral material challenges this paradigm by suggesting that disease-driving mechanisms may remain active months or years after the initial infection.

This distinction is critical. Residual injury is often difficult to reverse. Persistent biologic drivers, by contrast, may respond to targeted intervention.

Evidence increasingly suggests that Long COVID encompasses multiple biological subtypes. Viral persistence may predominate in some patients, whereas autoimmunity, endothelial dysfunction, mitochondrial impairment, or irreversible organ damage may be more important in others. The future of Long COVID treatment will likely require identification of these distinct phenotypes.

Clinical Correlates of Viral Persistence

Several symptom clusters appear particularly associated with evidence of persistent viral material.

These include:

Fatigue

Persistent fatigue remains the most common symptom reported in Long COVID cohorts.

Characteristics include:

Profound exhaustion
Reduced stamina
Failure of rest to restore function
Fluctuating severity

Many affected individuals describe fatigue as qualitatively different from ordinary tiredness.

Post-Exertional Symptom Exacerbation

A substantial subset of patients experience worsening symptoms following physical, cognitive, or emotional exertion.

Manifestations include:

Increased fatigue
Cognitive deterioration
Myalgias
Dysautonomia
Sleep disruption

Post-exertional symptom exacerbation resembles the phenomenon observed in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Cognitive Dysfunction

Patients frequently report:

Memory impairment
Reduced attention
Executive dysfunction
Slowed processing speed

Emerging evidence suggests persistent antigen-driven neuroinflammation may contribute significantly to these manifestations.

Dysautonomia

Persistent viral material may be linked to:

Postural orthostatic tachycardia syndrome (POTS)
Orthostatic hypotension
Heart-rate variability abnormalities
Temperature dysregulation

These disorders often produce profound functional impairment despite relatively normal routine testing.

Gastrointestinal Manifestations

Persistent gastrointestinal reservoirs may contribute to:

Abdominal pain
Altered bowel habits
Nausea
Food intolerance
Microbiome disruption

The gastrointestinal tract may represent one of the principal sites sustaining chronic immune activation.

Diagnostic Approaches

At present, no universally accepted clinical test exists for confirming viral persistence in Long COVID.

This represents one of the greatest challenges in the field.

Current diagnostic approaches focus on indirect evidence.

Blood-Based Biomarkers

Potential biomarkers under investigation include:

Spike Protein

Several studies have reported circulating spike protein months after infection.

Detection methods include:

Ultrasensitive immunoassays
Single-molecule assays
Mass spectrometry-based techniques

Persistent detection may indicate ongoing antigen release from tissue reservoirs.

Nucleocapsid Protein

Nucleocapsid fragments may provide complementary evidence of viral persistence.

Advantages include reduced confounding from vaccination-induced spike exposure.

Viral RNA

Highly sensitive molecular assays have occasionally identified viral RNA fragments in blood.

Interpretation remains challenging because RNA detection does not necessarily indicate replication-competent virus.

Tissue-Based Diagnostics

The most convincing evidence of persistence currently derives from tissue sampling.

Potential targets include:

Intestinal mucosa
Lymphoid tissue
Bone marrow
Olfactory tissue

Limitations include:

Invasiveness
Sampling error
Cost
Limited availability

Consequently, routine tissue assessment remains impractical for most patients.

Advanced Imaging

Emerging imaging technologies may permit noninvasive identification of persistent inflammatory activity.

Potential approaches include:

PET imaging
Neuroinflammatory tracers
Endothelial imaging
Molecular imaging of immune activation

These methods remain largely investigational.

Antiviral Therapeutic Strategies

If persistent viral material contributes to Long COVID pathogenesis, antiviral therapy represents a logical intervention.

Several approaches have been proposed.

Direct-Acting Antivirals

Nirmatrelvir/Ritonavir

Interest in nirmatrelvir/ritonavir arose following reports of symptom improvement among some Long COVID patients.

Potential mechanisms include:

Reduction of residual viral replication
Decreased antigen production
Lower inflammatory signaling

However, controlled studies have yielded mixed results.

Potential explanations include:

Inadequate treatment duration
Incorrect patient selection
Absence of active replication in some patients

Future trials may require biomarker-guided enrollment.

Remdesivir

Remdesivir remains one of the most extensively studied SARS-CoV-2 antivirals.

Its role in established Long COVID remains uncertain.

Potential utility may be greatest in patients demonstrating objective evidence of persistence.

Emerging Antivirals

Several next-generation agents are currently under development.

Ideal characteristics include:

High tissue penetration
Activity within viral reservoirs
Favorable safety profiles
Extended administration capability

Such agents may ultimately prove more effective than currently available therapies.

Immunomodulatory Therapies

Persistent viral antigens may drive immune dysregulation. Consequently, modulation of aberrant immune responses has emerged as another therapeutic strategy.

Low-Dose Naltrexone

Low-dose naltrexone has received considerable attention among Long COVID clinicians.

Potential mechanisms include:

Reduction of microglial activation
Modulation of inflammatory signaling
Improvement of neuroimmune regulation

Observational studies suggest possible benefit, although large randomized trials remain needed.

Corticosteroids

Corticosteroids can suppress inflammation effectively.

Potential advantages include:

Reduction of cytokine activity
Diminished tissue inflammation

Limitations include:

Immunosuppression
Metabolic adverse effects
Potential interference with viral clearance

Long-term use remains controversial.

Janus Kinase (JAK) Inhibitors

JAK inhibitors target inflammatory signaling pathways implicated in persistent immune activation.

Potential benefits include:

Cytokine suppression
Reduced inflammatory amplification

Further investigation is ongoing.

Intravenous Immunoglobulin

Intravenous immunoglobulin (IVIG) may benefit selected patients through:

Autoantibody neutralization
Immune modulation
Anti-inflammatory effects

Particular interest exists for patients exhibiting autoimmune features or small-fiber neuropathy.

Endothelial and Microvascular Therapies

Because endothelial dysfunction appears central to Long COVID pathophysiology, several therapies target vascular abnormalities.

Antiplatelet Strategies

Potential benefits include:

Reduction of platelet activation
Improvement of microvascular flow

Evidence remains preliminary.

Anticoagulation

The hypothesis that microvascular thrombosis contributes to symptoms has stimulated investigation of anticoagulant therapies.

Potential advantages include:

Improved capillary perfusion
Reduction of thrombotic burden

However, bleeding risks require careful consideration.

Large controlled trials remain necessary.

Endothelial-Protective Therapies

Potential agents include:

Statins
ACE inhibitors
Angiotensin receptor blockers
Nitric oxide–enhancing therapies

These interventions may improve endothelial function independent of antiviral activity.

Metabolic and Mitochondrial Therapies

Because mitochondrial dysfunction may contribute significantly to symptom generation, several metabolic interventions have attracted attention.

Examples include:

Coenzyme Q10
L-carnitine
Nicotinamide adenine dinucleotide (NAD+) precursors
Alpha-lipoic acid
Creatine

Evidence remains preliminary but biologically plausible.

Rehabilitation Strategies

Rehabilitation remains important but must be individualized.

Traditional graded exercise approaches may worsen symptoms in patients experiencing post-exertional symptom exacerbation.

Current recommendations increasingly emphasize:

Pacing
Energy conservation
Heart-rate monitoring
Autonomic stabilization
Structured symptom-guided activity

These approaches appear safer than rigid exercise escalation.

Precision Medicine Approaches

Future Long COVID management will likely depend upon biologic stratification.

Potential phenotypes include:

Viral Persistence Dominant

Characteristics:

Detectable viral antigens
Immune activation
Reservoir evidence

Potential treatment:

Antivirals

Autoimmune Dominant

Characteristics:

Autoantibodies
Immune dysregulation

Potential treatment:

Immunomodulation

Endothelial Dominant

Characteristics:

Vascular dysfunction
Microclot abnormalities

Potential treatment:

Endothelial-targeted therapies

Metabolic Dominant

Characteristics:

Mitochondrial dysfunction
Exercise intolerance

Potential treatment:

Metabolic interventions

Many patients likely exhibit overlapping phenotypes.

Future Research Priorities

Several questions remain unanswered.

Does Replication-Competent Virus Persist?

The distinction between residual antigen and active infection remains crucial.

What Defines a Viral Reservoir?

Precise characterization of reservoir tissues remains incomplete.

Why Do Only Some Patients Develop Long COVID?

Genetic, immunologic, and environmental factors likely influence susceptibility.

Which Biomarkers Best Predict Treatment Response?

Reliable biomarkers remain urgently needed.

Can Early Antiviral Therapy Prevent Long COVID?

Ongoing studies seek to determine whether prompt viral suppression reduces future risk.

Conclusions

Evidence supporting persistent viral material in Long COVID has expanded dramatically since the beginning of the pandemic. Viral RNA, spike protein, nucleocapsid protein, and other viral remnants have been identified in multiple tissues months and, in some cases, years following acute infection. These findings provide a biologically plausible explanation for many manifestations of Long COVID and support a model in which persistent antigens drive chronic immune activation, endothelial dysfunction, microvascular injury, mitochondrial impairment, neuroinflammation, and autonomic dysregulation.

Current evidence suggests that viral persistence is unlikely to represent the sole mechanism responsible for Long COVID. Rather, it appears to function as one component within a complex network of interacting biological processes. Nevertheless, persistent viral material remains among the most compelling and therapeutically actionable mechanisms identified to date.

The future of Long COVID medicine will likely depend upon precise biological phenotyping, biomarker-guided therapy, and combination treatment strategies targeting both viral reservoirs and downstream pathophysiologic consequences. Continued investigation of viral persistence promises not only to improve treatment of Long COVID but also to deepen understanding of chronic post-infectious disease more broadly.

Selected References (JAMA Style)

Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long COVID. N Engl J Med. 2022;386:1973-1975.
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.
Chertow D, Stein S, Ramelli S, et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Nature. 2022;612:758-763.
Swank Z, Senussi Y, Alter G, et al. Persistent circulating SARS-CoV-2 spike protein in post-acute COVID-19 sequelae. Clin Infect Dis. 2023.
Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 persistence and tissue distribution. Nature. 2022;612:758-763.
Putrino D, Peluso MJ, Nadkarni GN. Long COVID pathophysiology. Nat Rev Immunol. 2024.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146.
Pretorius E, Vlok M, Venter C, et al. Persistent clotting abnormalities and amyloid microclots in Long COVID. Cardiovasc Diabetol. 2022;21:1-18.
Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881-895.
RECOVER Consortium Investigators. Long COVID research priorities and mechanisms. JAMA. 2024.
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615.
Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259-264.
Yong SJ. Persistent brainstem dysfunction in Long COVID. Front Neurol. 2021;12:698169.
Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194-202.
Proal AD, VanElzakker MB. Viral persistence and chronic disease. Front Immunol. 2023;14:1197365.